Risks increased for peptic ulcer bleeding, uncomplicated peptic ulcer, lower GI bleeding, heart failure, HTN, CKD
TUESDAY, Dec. 17, 2024 (HealthDay News) — In older adults, acetaminophen use is associated with serious complications, according to a study published online Nov. 24 in Arthritis Care & Research.
Jaspreet Kaur, M.P.H., Ph.D., from the University of Nottingham in the United Kingdom, and colleagues examined the safety of oral acetaminophen at its therapeutic dose in adults aged 65 years and older in a population-based cohort study. Acetaminophen exposure was defined as at least two prescriptions within six months of the first prescription (index date). Propensity scores (PS) were calculated for acetaminophen prescription, and inverse probability treatment weighting using PS and PS-matched analyses were undertaken to account for confounding.
The study included 180,483 and 402,478 acetaminophen users and nonusers, respectively. The researchers observed associations for acetaminophen use with increased risks for peptic ulcer bleeding, uncomplicated peptic ulcers, lower gastrointestinal bleeding, heart failure, hypertension, and chronic kidney disease (adjusted hazard ratios, 1.24, 1.20, 1.36, 1.09, 1.07, and 1.19, respectively).
“Despite its perceived safety, acetaminophen is associated with several serious complications,” the authors write. “Given its minimal analgesic effectiveness, the use of acetaminophen as the first-line oral analgesic for long-term conditions in older people requires careful reconsideration.”
Abstract/Full Text (subscription or payment may be required)
Mortality Lowest at Hemoglobin Concentrations Above WHO Thresholds
Intrauterine Instillation of Mepivacaine Reduces Pain of IUD Placement
Spinal Cord Stimulation Cuts Pain, Improves Sensation With Diabetic Nerve Damage
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus
Therapies Compared for Newly Diagnosed Multiple Sclerosis